PLX Protalix Biotherapeutics
- 1.130
- -0.010-0.88%
- 1.150
- +0.020+1.77%
Protalix Biotherapeutics News
Protalix Biotherapeutics | ARS: Annual Report to Security Holders
Protalix Biotherapeutics | DEFA14A: Others
Protalix Biotherapeutics | 10-Q: Quarterly report
Protalix Biotherapeutics | 8-K: Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix Biotherapeutics | DEF 14A: Definitive information statements
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bashan Dror
Protalix Biotherapeutics | 10-K: Annual report
Protalix Biotherapeutics | 8-K: Current report
Protalix Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Angels Investments in Hi Tech Ltd(2.9%),Marius Nacht(2.9%)
Protalix Biotherapeutics | 8-K: Current report
Protalix Biotherapeutics: Q3 2023 Earnings Report
Protalix Biotherapeutics | 8-K: Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bashan Dror
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Boudes Pol F
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Melincoff Gwen A
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bar-Shalev Amos
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ben Zvi Shmuel
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Schwartz Aharon
Protalix Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Forster Eliot
Protalix Biotherapeutics | 3: Initial statement of beneficial ownership of securities-Director Forster Eliot
Analysis
Price Target
No Data
